Tag: pneumococcal vaccine market report

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

#Pneumococcal Vaccine Market Forecast: Value Set To Climb From $9.93 Billion To $12.76 Billion#_x000D_

The pneumococcal vaccine market size has experienced significant expansion over recent years. It is anticipated to increase from $9.4 billion in 2025 to $9.94 billion in 2026, at a compound annual growth rate (CAGR) of 5.7%. The market’s historic growth can be linked to the substantial burden of childhood pneumonia, its inclusion in national immunization programs, strong support from global health organizations, increasing awareness of invasive pneumococcal disease, and the proven efficacy of PCV vaccines._x000D_

_x000D_

The pneumococcal vaccine market is projected to experience substantial expansion over the coming years, with its size set to reach $12.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is driven by several factors, including the introduction of advanced PCV vaccines, wider adult vaccination guidelines, improved healthcare accessibility in developing nations, escalating worries about antimicrobial resistance, and governmental support for preventative immunization initiatives. Key trends expected in this period involve the development of conjugate vaccines to cover a broader range of serotypes, a heightened emphasis on immunization programs for children and the elderly, increasing use of combined and booster vaccination approaches, enhanced collaborations between public and private sectors for wider immunization coverage, and an expansion of preventive healthcare alongside national immunization calendars._x000D_

_x000D_

#Get A Free Sample Report With In-Depth Market Insights:#_x000D_

https://thebusinessresearchcompany.com/sample_request?id=11950&type=smp&name=Pneumococcal%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Pneumococcal Vaccine Market Development Factors: What’s Supporting Demand?#_x000D_

The increasing incidence of pneumococcal contamination is anticipated to boost the growth of the pneumococcal vaccine market. Pneumococcal contamination refers to infections caused by *Streptococcus pneumoniae* bacteria, including conditions such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine works by prompting the body to generate antibodies against these bacteria, thereby reducing or eliminating disease-carrying pathogens and toxins to safeguard children, the elderly, and individuals with weakened immune systems from various pneumococcal infections. For example, in July 2025, the Immunisation Coalition, an independent not-for-profit charity based in Australia, reported a consistent rise in cases of invasive pneumococcal disease (IPD), increasing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. This growing prevalence of pneumococcal contamination is thus a significant driver for the expansion of the pneumococcal vaccine market._x000D_

_x000D_

#Pneumococcal Vaccine Market Segmentation And Category Overview#_x000D_

The pneumococcal vaccine market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products_x000D_

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous_x000D_

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels_x000D_

4) By End User: Pediatrics, Adults_x000D_

_x000D_

Subsegments:_x000D_

1) By Prevnar 13: Pediatric Formulation, Adult Formulation _x000D_

2) By Synflorix: Pediatric Formulation, Adult Formulation _x000D_

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes _x000D_

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines _x000D_

_x000D_

#Pneumococcal Vaccine Market Transformation Trends: What Innovations Are Driving Change?#_x000D_

Key players within the pneumococcal vaccine market are developing novel offerings to enhance their market profitability. An example of this is the introduction of the V116 vaccine by Merck & Co Inc., a US-based pharmaceuticals company, in July 2023. This V116 vaccine aims to address the eight distinct serotypes of Streptococcus pneumoniae, which are largely accountable for adult pneumococcal disease. Demonstrating superior immunogenicity across multiple serotypes in adult populations when compared to existing pneumococcal vaccines, V116 has also elicited favorable immune responses in individuals who are both new to vaccination and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and its development is presently in Phase 3._x000D_

_x000D_

#Pneumococcal Vaccine Market Competitive Analysis Of Leading Industry Participants#_x000D_

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE _x000D_

_x000D_

#View The Full Pneumococcal Vaccine Market Report:#_x000D_

https://thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR_x000D_

_x000D_

#Pneumococcal Vaccine Market Geographic Landscape: Which Region Leads Industry Growth?#_x000D_

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Reach Out To Our Team:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas: +1 310-496-7795_x000D_

Asia: +44 7882 955267 & +91 8897263534_x000D_

Europe: +44 7882 955267_x000D_

Email us at: marketing@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Pneumococcal Vaccine Market Size Forecast: How Large Could The Market Become By 2030?

The pneumococcal vaccine market has experienced significant expansion in recent years, with its value projected to rise from $9.4 billion in 2025 to $9.94 billion by 2026, reflecting a compound annual growth rate of 5.7%. This past growth has been driven by several key factors, including a high burden of childhood pneumonia, the integration of these vaccines into national immunization schedules, robust backing from international health bodies, increased public awareness of invasive pneumococcal disease, and the well-documented effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience robust expansion over the coming years, reaching a valuation of $12.76 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is fueled by the introduction of next-generation PCV vaccines, broader adult vaccination recommendations, improved healthcare accessibility in emerging markets, heightened concerns over antimicrobial resistance, and increased government investment in preventive immunization programs. Key trends shaping this period include the development of conjugate vaccines targeting a wider range of serotypes, a stronger emphasis on immunization initiatives for both children and the elderly, growing adoption of combination and booster vaccination approaches, enhanced public-private collaborations to expand vaccine coverage, and a general shift toward preventive healthcare and the integration of vaccines into national immunization schedules.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pneumococcal Vaccine Market Growth Drivers And Industry Catalysts

The anticipated expansion of the pneumococcal vaccine market is being driven by the rising incidence of pneumococcal contamination. This type of contamination encompasses infections caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus, which includes conditions like pneumonia, bloodstream infections, ear infections, and sinus infections. By triggering the production of antibodies that target pneumococcal bacteria, the vaccine works to diminish or eliminate disease-causing organisms and their toxins, providing protection against various pneumococcal infections for children, the elderly, and individuals with compromised immune systems. For example, data from July 2025, released by the Immunisation Coalition—an independent non-profit charity based in Australia—indicates that cases of invasive pneumococcal disease (IPD) have risen consistently year over year, climbing from 1,869 in 2022 to 2,265 in 2023, and further increasing to 2,379 in 2024. Consequently, this growing prevalence of pneumococcal contamination is fueling momentum in the pneumococcal vaccine market.

Pneumococcal Vaccine Market Segment Analysis And Revenue Opportunities

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Pneumococcal Vaccine Market Trends Influencing Long-Term Demand

Key players in the pneumococcal vaccine market are developing new products to enhance their competitive edge and profitability. For example, in July 2023, Merck & Co Inc., a pharmaceutical company headquartered in the United States, launched the V116 vaccine. This vaccine is specifically designed to address eight distinct serotypes of Streptococcus pneumoniae that are most commonly linked to pneumococcal disease in adults. V116 has demonstrated superior immunogenicity compared to other pneumococcal vaccines across a range of serotypes in adult populations, and it has elicited robust immune responses in both individuals who have never been vaccinated and those who have received prior vaccinations. The U.S. Food and Drug Administration (FDA) has granted V116 breakthrough therapy designation, and it is currently undergoing Phase 3 clinical trials.

Pneumococcal Vaccine Market Leading Players Shaping Industry Direction

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Access The Complete Pneumococcal Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pneumococcal Vaccine Market Geographic Distribution And Regional Opportunities

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Pneumococcal Vaccine Market Progress Through 2030?

The pneumococcal vaccine market has experienced significant expansion over recent years. This market is projected to expand from $9.4 billion in 2025 to $9.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. Historically, this growth was driven by factors such as the substantial burden of childhood pneumonia, the integration into national immunization programs, robust backing from global health organizations, increasing public awareness of invasive pneumococcal disease, and the demonstrated effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience substantial expansion in the coming years, anticipated to reach $12.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors contributing to this growth during the forecast period include the introduction of next-generation PCV vaccines, wider adult vaccination recommendations, improved healthcare accessibility in developing nations, escalating worries about antimicrobial resistance, and government investment in preventive immunization programs. Key trends emerging in the forecast period encompass the broadening of conjugate vaccines to cover more serotypes, an intensified emphasis on immunization programs for children and the elderly, the increasing implementation of combination and booster vaccination approaches, enhanced public-private collaborations to boost immunization coverage, and the expansion of preventive healthcare alongside national immunization schedules.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Primary Factors Are Fueling The Expansion Of The Pneumococcal Vaccine Market?

The rising incidence of pneumococcal contamination is anticipated to fuel the expansion of the pneumococcal vaccine market in the coming years. This type of contamination signifies infections stemming from the bacterium Streptococcus pneumoniae, also known as pneumococcus, manifesting as conditions like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine functions by prompting the body to generate antibodies against pneumococcal bacteria, effectively reducing or eliminating disease-causing bacteria and their toxins, thereby safeguarding children, the elderly, and individuals with compromised immune systems against various forms of pneumococcal infections. As an illustration, data from July 2025, provided by the Immunisation Coalition, an Australia-based, independent not-for-profit charity, indicates a consistent annual rise in invasive pneumococcal disease (IPD) cases, escalating from 1,869 in 2022 to 2,265 in 2023, and subsequently to 2,379 in 2024. Consequently, the escalating occurrence of pneumococcal contamination is serving as a primary impetus for the growth of the pneumococcal vaccine market.

What Key Segment Areas Are Included In The Pneumococcal Vaccine Market Assessment?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

Which Trends Are Guiding The Development Of The Pneumococcal Vaccine Market?

Leading companies within the pneumococcal vaccine market are introducing innovative products to boost their market profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, launched its V116 vaccine. This V116 vaccine is engineered to address the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Relative to other pneumococcal vaccines, V116 has exhibited enhanced immunogenicity across various serotypes in adult populations, and it has also generated positive immune responses in individuals who have not received prior vaccination as well as those previously vaccinated. The U.S. Food and Drug Administration (FDA) has categorized V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Who Are The Leading Firms Participating In The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Access The Complete Pneumococcal Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Region Stands As The Largest Contributor To The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pneumococcal Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Pneumococcal Vaccine Market During 2026–2030?

The pneumococcal vaccine market size has shown strong growth in recent years. It is anticipated to expand from $9.4 billion in 2025 to $9.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic growth is attributable to several factors, including the significant burden of childhood pneumonia, the incorporation into national immunization programs, substantial backing from global health organizations, increasing awareness of invasive pneumococcal disease, and the demonstrated effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience substantial expansion over the coming years, reaching a valuation of $12.76 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is driven by factors such as the introduction of next-generation PCV vaccines, wider recommendations for adult vaccinations, improved access to healthcare in developing nations, escalating concerns regarding antimicrobial resistance, and government financial support for preventive immunization initiatives. Key trends anticipated in this period include the broadening of conjugate vaccines to cover a greater range of serotypes, a heightened emphasis on immunization programs for children and the elderly, the increasing uptake of combination and booster vaccination methods, enhanced public-private collaborations to boost immunization coverage, and the overall rise in preventive healthcare practices and national immunization schedules.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Significant Factors Are Influencing The Pneumococcal Vaccine Market Expansion?

The rising occurrence of pneumococcal contamination is projected to boost the expansion of the pneumococcal vaccine market in the future. This contamination involves any infection stemming from bacteria known as Streptococcus pneumoniae or pneumococcus, encompassing conditions like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine works by encouraging the body to generate antibodies against pneumococcal bacteria, aiming to diminish or eliminate disease-causing bacteria and toxins, thereby safeguarding children, older adults, and individuals with compromised immune systems from various forms of pneumococcal infections. A notable example comes from July 2025, where the Immunisation Coalition, an independent not-for-profit charity located in Australia, reported a consistent annual rise in invasive pneumococcal disease (IPD) cases, escalating from 1,869 in 2022 to 2,265 in 2023, and further to 2,379 in 2024. Consequently, the heightened prevalence of pneumococcal contamination serves as a key driver for the expansion of the pneumococcal vaccine market.

How Are Different Segments Classified In The Pneumococcal Vaccine Market Segment Analysis?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Emerging Trends Are Seen In The Pneumococcal Vaccine Market?

Leading companies active in the pneumococcal vaccine market are introducing new products to boost their market profitability. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals firm, unveiled the V116 vaccine. V116 is designed to target the eight specific serotypes of Streptococcus pneumoniae primarily causing adult pneumococcal disease. Exhibiting enhanced immunogenicity for various serotypes in adult populations compared to other pneumococcal vaccines, V116 has also generated positive immune responses in both individuals new to vaccination and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Who Are The Companies Driving Activity In The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Get The Full Pneumococcal Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Where Is The Pneumococcal Vaccine Market Primarily Concentrated By Region?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pneumococcal Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Pneumococcal Vaccine Market Across 2026–2030?

The pneumococcal vaccine market has experienced robust expansion in recent times. Projections indicate it will expand from $9.4 billion in 2025 to reach $9.94 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. Historically, this growth is linked to factors such as a substantial burden of childhood pneumonia, the integration of these vaccines into national immunization programs, considerable backing from global health organizations, increased understanding of invasive pneumococcal disease, and the established effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience robust expansion over the forthcoming years. By 2030, this market is anticipated to reach a valuation of $12.76 billion, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated expansion during the forecast period is driven by several factors, including the introduction of advanced PCV vaccines, wider recommendations for adult vaccinations, improved access to healthcare services in developing nations, escalating worries regarding antimicrobial resistance, and governmental financial support for preventative immunization initiatives. Significant developments expected during this timeframe encompass the wider application of conjugate vaccines to cover more serotypes, heightened emphasis on immunization programs for children and the elderly, a greater uptake of vaccination strategies involving combinations and boosters, fortified collaborations between public and private sectors to enhance immunization reach, and an overall increase in preventive healthcare practices and national immunization plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Drivers Are Shaping The Future Growth Of The Pneumococcal Vaccine Market?

The increasing incidence of pneumococcal contamination is anticipated to drive the expansion of the pneumococcal vaccine market moving forward. Pneumococcal contamination refers to any infection caused by bacteria known as Streptococcus pneumoniae or pneumococcus, including ailments such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body’s production of antibodies against pneumococcal bacteria to diminish or eradicate disease-carrying bacteria and toxins, thereby protecting children, the elderly, and those with compromised immune systems from numerous types of pneumococcal infections. For example, in July 2025, the Immunisation Coalition, an independent not-for-profit charity based in Australia, reported that cases of invasive pneumococcal disease (IPD) have steadily risen each year, increasing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. Thus, the growing prevalence of pneumococcal contamination is a key driver for the growth of the pneumococcal vaccine market.

What Segmentation Levels Are Considered In The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Projected To Affect The Pneumococcal Vaccine Market?

Leading companies active in the pneumococcal vaccine market are innovating new products to boost their market profitability. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, introduced its V116 vaccine. V116 is engineered to target the eight distinct serotypes of Streptococcus pneumoniae that are the primary cause of adult pneumococcal disease. In comparison to other pneumococcal vaccines, V116 has exhibited enhanced immunogenicity for a range of serotypes within adult populations, and it has also generated positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Which Leading Firms Are Contributing To The Growth Of The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Read the full pneumococcal vaccine market report here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Geographic Regions Are Influencing Demand In The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pneumococcal Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Pneumococcal Vaccine Market Across 2026–2030?

The pneumococcal vaccine market has experienced robust expansion in recent times. Projections indicate it will expand from $9.4 billion in 2025 to reach $9.94 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. Historically, this growth is linked to factors such as a substantial burden of childhood pneumonia, the integration of these vaccines into national immunization programs, considerable backing from global health organizations, increased understanding of invasive pneumococcal disease, and the established effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience robust expansion over the forthcoming years. By 2030, this market is anticipated to reach a valuation of $12.76 billion, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated expansion during the forecast period is driven by several factors, including the introduction of advanced PCV vaccines, wider recommendations for adult vaccinations, improved access to healthcare services in developing nations, escalating worries regarding antimicrobial resistance, and governmental financial support for preventative immunization initiatives. Significant developments expected during this timeframe encompass the wider application of conjugate vaccines to cover more serotypes, heightened emphasis on immunization programs for children and the elderly, a greater uptake of vaccination strategies involving combinations and boosters, fortified collaborations between public and private sectors to enhance immunization reach, and an overall increase in preventive healthcare practices and national immunization plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Drivers Are Shaping The Future Growth Of The Pneumococcal Vaccine Market?

The increasing incidence of pneumococcal contamination is anticipated to drive the expansion of the pneumococcal vaccine market moving forward. Pneumococcal contamination refers to any infection caused by bacteria known as Streptococcus pneumoniae or pneumococcus, including ailments such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body’s production of antibodies against pneumococcal bacteria to diminish or eradicate disease-carrying bacteria and toxins, thereby protecting children, the elderly, and those with compromised immune systems from numerous types of pneumococcal infections. For example, in July 2025, the Immunisation Coalition, an independent not-for-profit charity based in Australia, reported that cases of invasive pneumococcal disease (IPD) have steadily risen each year, increasing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. Thus, the growing prevalence of pneumococcal contamination is a key driver for the growth of the pneumococcal vaccine market.

What Segmentation Levels Are Considered In The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Projected To Affect The Pneumococcal Vaccine Market?

Leading companies active in the pneumococcal vaccine market are innovating new products to boost their market profitability. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, introduced its V116 vaccine. V116 is engineered to target the eight distinct serotypes of Streptococcus pneumoniae that are the primary cause of adult pneumococcal disease. In comparison to other pneumococcal vaccines, V116 has exhibited enhanced immunogenicity for a range of serotypes within adult populations, and it has also generated positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Which Leading Firms Are Contributing To The Growth Of The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Read the full pneumococcal vaccine market report here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Geographic Regions Are Influencing Demand In The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pneumococcal Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Pneumococcal Vaccine Market Across 2026–2030?

The pneumococcal vaccine market has experienced robust expansion in recent times. Projections indicate it will expand from $9.4 billion in 2025 to reach $9.94 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. Historically, this growth is linked to factors such as a substantial burden of childhood pneumonia, the integration of these vaccines into national immunization programs, considerable backing from global health organizations, increased understanding of invasive pneumococcal disease, and the established effectiveness of PCV vaccines.

The pneumococcal vaccine market is projected to experience robust expansion over the forthcoming years. By 2030, this market is anticipated to reach a valuation of $12.76 billion, exhibiting a compound annual growth rate (CAGR) of 6.5%. This anticipated expansion during the forecast period is driven by several factors, including the introduction of advanced PCV vaccines, wider recommendations for adult vaccinations, improved access to healthcare services in developing nations, escalating worries regarding antimicrobial resistance, and governmental financial support for preventative immunization initiatives. Significant developments expected during this timeframe encompass the wider application of conjugate vaccines to cover more serotypes, heightened emphasis on immunization programs for children and the elderly, a greater uptake of vaccination strategies involving combinations and boosters, fortified collaborations between public and private sectors to enhance immunization reach, and an overall increase in preventive healthcare practices and national immunization plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Drivers Are Shaping The Future Growth Of The Pneumococcal Vaccine Market?

The increasing incidence of pneumococcal contamination is anticipated to drive the expansion of the pneumococcal vaccine market moving forward. Pneumococcal contamination refers to any infection caused by bacteria known as Streptococcus pneumoniae or pneumococcus, including ailments such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body’s production of antibodies against pneumococcal bacteria to diminish or eradicate disease-carrying bacteria and toxins, thereby protecting children, the elderly, and those with compromised immune systems from numerous types of pneumococcal infections. For example, in July 2025, the Immunisation Coalition, an independent not-for-profit charity based in Australia, reported that cases of invasive pneumococcal disease (IPD) have steadily risen each year, increasing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. Thus, the growing prevalence of pneumococcal contamination is a key driver for the growth of the pneumococcal vaccine market.

What Segmentation Levels Are Considered In The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Trends Are Projected To Affect The Pneumococcal Vaccine Market?

Leading companies active in the pneumococcal vaccine market are innovating new products to boost their market profitability. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, introduced its V116 vaccine. V116 is engineered to target the eight distinct serotypes of Streptococcus pneumoniae that are the primary cause of adult pneumococcal disease. In comparison to other pneumococcal vaccines, V116 has exhibited enhanced immunogenicity for a range of serotypes within adult populations, and it has also generated positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is presently in Phase 3 development.

Which Leading Firms Are Contributing To The Growth Of The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Read the full pneumococcal vaccine market report here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Geographic Regions Are Influencing Demand In The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pneumococcal Vaccine Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pneumococcal vaccine market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Pneumococcal Vaccine Market from 2026 to 2030?

The size of the pneumococcal vaccine market has shown vigorous expansion over recent years. This market is projected to expand from $9.4 billion in 2025 to $9.94 billion by 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The historical growth can be linked to several contributing factors: a significant prevalence of childhood pneumonia, their incorporation into national immunization schedules, robust endorsement from international health bodies, heightened recognition of invasive pneumococcal disease, and the established effectiveness of PCV vaccines.

The pneumococcal vaccine market size is anticipated to experience substantial expansion over the coming years. It is projected to reach $12.76 billion by 2030, showing a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period can be attributed to several factors, including the introduction of advanced PCV vaccines, wider recommendations for adult vaccination, improved access to healthcare in developing nations, growing worries about antimicrobial resistance, and governmental support for preventative immunization efforts. Key trends anticipated in this period encompass the development of conjugate vaccines for a broader range of serotype protection, a heightened emphasis on vaccination initiatives for children and the elderly, the increasing integration of combination and booster vaccination approaches, stronger collaborations between public and private sectors for wider immunization coverage, and an overall increase in preventive healthcare practices and national immunization schedules.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

What Drivers Are Affecting Demand In The Pneumococcal Vaccine Market?

The escalating occurrence of pneumococcal contamination is projected to propel the growth of the pneumococcal vaccine market moving forward. Pneumococcal contamination refers to any infection caused by Streptococcus pneumoniae bacteria, or pneumococcus, which can manifest as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine functions by encouraging the body to create antibodies against these bacteria, thus reducing or destroying disease-carrying pathogens and toxins to safeguard children, the elderly, and individuals with weakened immune systems from various pneumococcal infections. For example, in July 2025, an independent not-for-profit charity based in Australia, the Immunisation Coalition, observed a steady increase in cases of invasive pneumococcal disease (IPD) annually, rising from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. This increasing prevalence of pneumococcal contamination is therefore a significant driver for the growth of the pneumococcal vaccine market.

Which Segment Groups Are Influencing The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

How Are New Market Trends Shaping The Landscape Of The Pneumococcal Vaccine Market?

Key players in the pneumococcal vaccine market are introducing innovative products to enhance their profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, unveiled the V116 vaccine. V116 is designed to target the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Compared to existing pneumococcal vaccines, V116 has exhibited improved immunogenicity across various serotypes in adult populations and has also generated positive immune responses in both individuals new to vaccination and those previously vaccinated. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is presently undergoing Phase 3 development.

Who Are The Primary Competitors In The Global Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pneumococcal Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2026, By The Business Research Company

Pneumococcal Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Meningococcal Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-vaccines-global-market-report

Meningococcal Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/meningococcal-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pneumococcal vaccine market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Pneumococcal Vaccine Market Now And By 2029?

The pneumococcal vaccine market has experienced strong growth in recent years. It is projected to expand from $8.94 billion in 2024 to $9.4 billion in 2025, achieving a compound annual growth rate (CAGR) of 5.2%. The historical growth of this market can be attributed to factors such as the discovery of streptococcus pneumoniae, significant public health concern, early vaccination efforts, advancements in healthcare, and changes in vaccine policy.

The pneumococcal vaccine market is projected to experience robust expansion over the coming years. This market is anticipated to reach $11.9 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. Factors driving this growth during the forecast period include the evolution of pneumococcal strains, ongoing research and development efforts, evolving immunization priorities, broader vaccine access, and an aging global population. Key trends for the upcoming period encompass the creation of multivalent vaccines, widespread vaccination among at-risk populations, strategies to enhance vaccine efficacy, robust education and awareness initiatives, and a focus on infant immunization.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Which Long-Term Drivers Are Expected To Sustain The Pneumococcal Vaccine Market?

The rising occurrence of pneumococcal contamination is anticipated to fuel expansion within the pneumococcal vaccine market in the future. This type of contamination signifies any infection resulting from the bacteria Streptococcus pneumoniae or pneumococcus, including ailments like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine works by prompting the body to generate antibodies combatting pneumococcal bacteria, thereby diminishing or eradicating disease-causing bacteria and their toxins to safeguard children, seniors, and individuals with compromised immune systems against various forms of pneumococcal infections. For example, data from January 2022, provided by the Center for Disease Control and Prevention, a US-based public health authority, indicates that Pneumococcal pneumonia leads to an approximate 150,000 hospitalizations annually in the United States, constituting as much as 30% of adult community-acquired pneumonia. Consequently, the growing frequency of pneumococcal contamination is a key impetus for the expansion of the pneumococcal vaccine market.

How Is The Pneumococcal Vaccine Market Classified By Different Segments?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Current And Upcoming Trends Are Shaping The Pneumococcal Vaccine Market?

Leading companies operating in the pneumococcal vaccine market are introducing new products to enhance their profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, launched its V116 vaccine. V116 is designed to target the eight distinct serotypes of Streptococcus pneumoniae primarily responsible for adult pneumococcal disease. Compared to other pneumococcal vaccines, V116 exhibited superior immunogenicity for various serotypes in adult populations and generated positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has recognized V116 as a breakthrough therapy, and it is currently undergoing Phase 3 development.

Who Are The Primary Market Leaders In The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2025, By The Business Research Company

Medical Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

Medical Waste Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Tubing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-tubing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Pneumococcal Vaccine Market From 2025 To 2034?

The pneumococcal vaccine market size has demonstrated significant growth over recent years. It is anticipated to increase from $8.94 billion in 2024 to $9.4 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. The expansion observed in past periods is attributable to the discovery of streptococcus pneumoniae, heightened public health concern, pioneering vaccination efforts, ongoing healthcare advancements, and modifications in vaccine policy.

The pneumococcal vaccine market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $11.9 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. Factors driving this growth during the forecast period include the evolution of pneumococcal strains, ongoing research and development efforts, evolving immunization priorities, broader access to vaccines, and an aging global population. Key trends anticipated during this period encompass the creation of multivalent vaccines, expanded vaccination for at-risk populations, strategies to enhance vaccine efficacy, robust education and awareness initiatives, and focused immunization for infants.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Which Factors And Drivers Are Influencing The Pneumococcal Vaccine Market In 2025?

The rising occurrence of pneumococcal infections is anticipated to boost the expansion of the pneumococcal vaccine market in the future. Pneumococcal contamination refers to any infection caused by the bacterium Streptococcus pneumoniae or pneumococcus, presenting as conditions such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine works by stimulating the body to produce antibodies against these pneumococcal bacteria, thereby reducing or eliminating disease-carrying bacteria and toxins. This process helps protect children, the elderly, and individuals with weakened immune systems from various types of pneumococcal infections. For instance, in January 2022, according to the Center for Disease Control and Prevention, a US-based public health agency, pneumococcal pneumonia is responsible for an estimated 150,000 hospitalizations annually in the United States, making up to 30% of adult community-acquired pneumonia cases. Therefore, the increasing prevalence of pneumococcal contamination is a key driver for the growth of the pneumococcal vaccine market.

What Are The Primary Types Of Segments Analyzed In The Pneumococcal Vaccine Market?

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

Subsegments:

1) By Prevnar 13: Pediatric Formulation, Adult Formulation

2) By Synflorix: Pediatric Formulation, Adult Formulation

3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes

4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Are The Latest Industry Trends Transforming The Pneumococcal Vaccine Market?

Leading companies in the pneumococcal vaccine market are developing new products to enhance their profitability. For example, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company, introduced its V116 vaccine. V116 is designed to target the eight distinct serotypes of Streptococcus pneumoniae that are mainly responsible for adult pneumococcal disease. In comparison to other pneumococcal vaccines, V116 has exhibited improved immunogenicity for a range of serotypes in adult populations, and it has also generated positive immune responses in both individuals new to vaccination and those who have been previously vaccinated. The U.S. Food and Drug Administration (FDA) has granted V116 breakthrough therapy designation, and it is presently in Phase 3 development.

Who Are The Major Companies Operating In The Pneumococcal Vaccine Market?

Major companies operating in the pneumococcal vaccine market include Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Which Region Currently Holds The Largest Share Of The Pneumococcal Vaccine Market?

North America was the largest region in the pneumococcal vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pneumococcal Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11950&type=smp

Browse Through More Reports Similar to the Global Pneumococcal Vaccine Market 2025, By The Business Research Company

Medical Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-equipment-global-market-report

Medical Waste Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-waste-management-global-market-report

Medical Tubing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/medical-tubing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model